Compare · COR vs MCK
COR vs MCK
Side-by-side comparison of Cencora Inc. (COR) and McKesson Corporation (MCK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both COR and MCK operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $116.43B, about 1.8x COR ($65.15B).
- Over the past year, COR is up 4.9% and MCK is up 27.8% - MCK leads by 22.9 points.
- COR has been more active in the news (6 items in the past 4 weeks vs 4 for MCK).
- Both have 25 recent analyst ratings on file.
- Company
- Cencora Inc.
- McKesson Corporation
- Price
- $340.81-0.14%
- $1005.29+0.65%
- Market cap
- $65.15B
- $116.43B
- 1M return
- +10.16%
- +14.29%
- 1Y return
- +4.92%
- +27.82%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 25
Cencora Inc.
CoreSite Realty Corporation (NYSE:COR) delivers secure, reliable, high-performance data center, cloud access and interconnection solutions to a growing customer ecosystem across eight key North American markets. More than 1,375 of the world's leading enterprises, network operators, cloud providers, and supporting service providers choose CoreSite to connect, protect and optimize their performance-sensitive data, applications and computing workloads. Our scalable, flexible solutions and 460+ dedicated employees consistently deliver unmatched data center options  all of which leads to a best-in-class customer experience and lasting relationships.
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest COR
- SEC Form 4 filed by Cencora Inc.
- SEC Form 4 filed by Cencora Inc.
- Cencora Announces Date and Time for Fourth Quarter Fiscal 2026 Earnings Release
- New insider Sanchez Robert E claimed ownership of 197 shares (SEC Form 3)
- Cencora Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Cencora Elects Robert E. Sanchez to Its Board of Directors
- Director Greenberg Lon R sold $411,264 worth of shares (1,280 units at $321.30), decreasing direct ownership by 7% to 17,128 units (SEC Form 4)
- SVP & Chief Accounting Officer Krikorian Lazarus sold $321,080 worth of shares (985 units at $325.97) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 16,169 units (SEC Form 4)
- Executive Vice President Campbell Elizabeth S sold $3,662,663 worth of shares (11,300 units at $324.12), decreasing direct ownership by 37% to 19,455 units (SEC Form 4)
- RBC Capital Mkts initiated coverage on Cencora with a new price target
Latest MCK
- SEC Form 8-K filed by McKesson Corporation
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health
- McKesson Corporation Extends Pharmaceutical Distribution Agreement with CVS Health
- McKesson Corporation Announces Second Quarter Fiscal 2027 Earnings Release Date
- SVP, Controller & CAO Rutledge Napoleon B Jr sold $98,951 worth of shares (111 units at $891.45) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 521 units (SEC Form 4)
- McKesson Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)